3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
164
Other hematologic neoplasm
31
Sarcoma
7
Plasma cell
7
Dermatologic
7
CNS
7
Myeloid
6
Classical hematology
5
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
Other neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Neuroendocrine Tumors
69
Carcinoma, Neuroendocrine
26
Pheochromocytoma
23
Thyroid Cancer, Papillary
21
Pituitary Neoplasms
21
Thyroid Neoplasms
20
Adrenocortical Carcinoma
18
Paraganglioma
15
Multiple Endocrine Neoplasia Type 1
12
Sarcoma
11
Neuroblastoma
11
Small Cell Lung Carcinoma
10
Neoplasms
10
Melanoma
9
Lung Neoplasms
9
Carcinoid Tumor
9
Adrenal Gland Neoplasms
9
Adenoma, Islet Cell
9
Pancreatic Neoplasms
8
Gastro-enteropancreatic neuroendocrine tumor
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Medullary
8
Adenocarcinoma, Follicular
8
Thyroid Carcinoma, Anaplastic
7
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Cushing Syndrome
7
Cholangiocarcinoma
7
Central Nervous System Neoplasms
7
Breast Neoplasms
7
Interventions
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Endocrine
×
90 days
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled